Enterprise Value
40.69M
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
1.76%
Insider Ownership
21.32%
Institutional Own.
11.23%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MB-107 Details X-Linked severe combined immunodeficiency | Phase 2 Initiation | |
MB-207 Details X-Linked severe combined immunodeficiency, Myelofibrosis | Phase 2 Initiation | |
LV-RAG1 (MB-110) Details RAG1-SCID | Phase 1/2 Data readout | |
MB-102 (CD123) Details High risk myelodysplastic syndromes , Blastic plasmacytoid dendritic cell neoplasm, Acute myeloid leukemia, Cancer | Phase 1/2 Data readout | |
MB-106 (CD20) Details Non-Hodgkin lymphoma, Lymphoma, Chronic lymphocytic leukemia, Cancer | Phase 1/2 Data readout | |
MB-104 Details Multiple myeloma, Solid tumor/s, Cancer | Phase 1 Data readout | |
MB-103 Details Glioblastoma, Metastatic breast cancer to brain, Cancer | Phase 1 Data readout | |
MB-105 (PSCA) Details Prostate cancer, Multiple myeloma, Cancer | Phase 1 Data readout | |
MB-101 (IL-13Ra2) Details Glioblastoma, Ependymoma, Medulloblastoma, Leptomeningeal brain tumors | Phase 1 Update |